KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2025)

Historic EBT Margin for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q3 2025 value amounting to 207.93%.

  • Ginkgo Bioworks Holdings' EBT Margin fell 1441700.0% to 207.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 188.29%, marking a year-over-year increase of 1106500.0%. This contributed to the annual value of 241.15% for FY2024, which is 1139600.0% up from last year.
  • As of Q3 2025, Ginkgo Bioworks Holdings' EBT Margin stood at 207.93%, which was down 1441700.0% from 122.13% recorded in Q2 2025.
  • Over the past 5 years, Ginkgo Bioworks Holdings' EBT Margin peaked at 63.76% during Q3 2024, and registered a low of 1081.31% during Q4 2021.
  • Over the past 5 years, Ginkgo Bioworks Holdings' median EBT Margin value was 245.99% (recorded in 2024), while the average stood at 357.98%.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by -9366000bps in 2021, then surged by 8901800bps in 2022.
  • Over the past 5 years, Ginkgo Bioworks Holdings' EBT Margin (Quarter) stood at 1081.31% in 2021, then surged by 82bps to 191.13% in 2022, then plummeted by -219bps to 609.67% in 2023, then surged by 60bps to 245.99% in 2024, then rose by 15bps to 207.93% in 2025.
  • Its EBT Margin was 207.93% in Q3 2025, compared to 122.13% in Q2 2025 and 188.06% in Q1 2025.